SCHEMBL2654625

SCHEMBL2654625

O=C(Nc1ccccn1)[C@H](CC1CCOCC1)c1ccc(S(=O)(=O)C2CC2)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.56
GCK P35557 17/20 0.51
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126322 0.91 GCK (0.54) KCNH2GCK
SCHEMBL9070770 0.89 KCNH2 (0.55) KCNH2GCK
SCHEMBL5115061 0.89 KCNH2 (0.71) KCNH2GCK
SCHEMBL2655582 0.88 KCNH2 (0.53) KCNH2GCK
SCHEMBL2656905 0.86 KCNH2 (0.54) KCNH2GCK
SCHEMBL4178604 0.85 GCK (0.69) GCK
SCHEMBL2668363 0.85 KCNH2 (0.57) KCNH2GCK
SCHEMBL2668368 0.85 KCNH2 (0.50) KCNH2GCK
SCHEMBL2668367 0.84 KCNH2 (0.51) KCNH2GCK
SCHEMBL2668362 0.83 GCK (0.57) KCNH2GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
US-20080293730-A1 Tricyclo Substituted Amides PROSIDION LIMITED (GB) 2008-11-27 US disclosed
EP-1948645-A1 TRICYCLO SUBSTITUTED AMIDES Prosidion Limited (GB) 2008-07-30 EP disclosed
WO-2007051846-A1 TRICYCLO SUBSTITUTED AMIDES PROSIDION LTD (GB) 2007-05-10 WO disclosed
WO-2007051846-A1 TRICYCLO SUBSTITUTED AMIDES PROSIDION LTD (GB) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293730-A1 Tricyclo Substituted Amides GPR119, SLC5A2, SLC5A1 KCNH2 1431/4885GCK 38/4885S1PR1 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.